Key Insights

Highlights

Success Rate

88% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

5.8%

3 terminated out of 52 trials

Success Rate

87.5%

+1.0% vs benchmark

Late-Stage Pipeline

4%

2 trials in Phase 3/4

Results Transparency

24%

5 of 21 completed with results

Key Signals

5 with results88% success

Data Visualizations

Phase Distribution

27Total
Not Applicable (10)
Early P 1 (1)
P 1 (4)
P 2 (10)
P 3 (2)

Trial Status

Completed21
Unknown8
Recruiting8
Active Not Recruiting6
Withdrawn3
Terminated3

Trial Success Rate

87.5%

Benchmark: 86.5%

Based on 21 completed trials

Clinical Trials (52)

Showing 20 of 20 trials
NCT01276470RecruitingPrimary

Environmental Risk Factors for the Anti-synthetase Syndrome

NCT01734369Completed

Environmental Risk Factors for Myositis in Military Personnel

NCT07552220Not Yet RecruitingPrimary

Muscle Imaging Project Using ANatomopathology and Full Field Optical Coherence Tomography

NCT05895786Phase 3RecruitingPrimary

A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]

NCT05979441Phase 3Enrolling By InvitationPrimary

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy

NCT05379634Phase 2Active Not RecruitingPrimary

A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies

NCT07502989Recruiting

Muscle Health Measurements Using Electrical Impedance Myography

NCT01432613Not ApplicableCompletedPrimary

Diagnostic Accuracy of Whole Body Magnetic Resonance Imaging in Inflammatory Myopathies

NCT02450396Withdrawn

Pregnancy and Medically Assisted Conception in Rare Diseases

NCT05251415Recruiting

Clinico-biological Collection to Investigate the Physiopathology of Systemic Autoimmune Diseases

NCT05832034Phase 2Active Not Recruiting

Add-on Intravenous Immunoglobulins in Early Myositis

NCT07374107Recruiting

MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS)

NCT06991114Phase 2Recruiting

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

NCT06925542Phase 1Recruiting

A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

NCT07012057Phase 2WithdrawnPrimary

Study of Deucravacitinib for Refractory Adults With Dermatomyositis/Juvenile Dermatomyositis

NCT06284954Phase 2Active Not Recruiting

A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis

NCT03912428Phase 1TerminatedPrimary

Novel PET Radioligand as an Inflammatory Biomarker in Musculoskeletal Conditions

NCT05523167Phase 2Active Not Recruiting

A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

NCT06966739CompletedPrimary

Multispectral Optoacustic Imaging in Patients With Myositis

NCT02468895Active Not RecruitingPrimary

MYOPROSP - a Prospective Cohort Study in Myositis

Scroll to load more

Research Network

Activity Timeline